On September 9, 2016, Taro Pharmaceutical revealed that it and two of its senior officers received grand jury subpoenas in connection with a federal antitrust investigation into generic drug pricing. Following this news, Taro stock dropped $4.94 per share or roughly 4% from its previous closing price to close at $119.42 per share on September 12, 2016.
If you are aware of any facts relating to this investigation, or purchased shares Taro on or before September 9, 2016, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/taro. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-taro-pharmaceutical-industries-ltd-taro-300348445.html
SOURCE Bronstein, Gewirtz & Grossman, LLC